>
Nkarta Inc logo

NKTX - Nkarta Inc Share Price

$34.87 -1.8  -4.9%

Last Trade - 16/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £826.8m
Enterprise Value £599.1m
Revenue £n/a
Position in Universe 2714th / 6850
Bullish
Bearish
Unlock NKTX Revenue
Momentum
Relative Strength (%)
1m -27.5%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -55.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 6.55 0.12 0.000 -100.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, NkartaInc revenues decreased from $115K to $0K. Net lossincreased from $21.1M to $91.4M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Change in fair value of preferred stock decreasefrom $1.3M (income) to $40.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NKTX Revenue Unlock NKTX Revenue

Net Income

NKTX Net Income Unlock NKTX Revenue

Normalised EPS

NKTX Normalised EPS Unlock NKTX Revenue

PE Ratio Range

NKTX PE Ratio Range Unlock NKTX Revenue

Dividend Yield Range

NKTX Dividend Yield Range Unlock NKTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NKTX EPS Forecasts Unlock NKTX Revenue
Profile Summary

Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety, and mbIL-15. This platform is modular, which enables optimization of different ways to enhance the natural signaling of engineered cells, as well as the ability to attach and optimize new targeting receptors. The Company’s lead product candidates are NKX101 and NKX019. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells and understanding of NK cell biology.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
No. of Shareholders: 40
No. of Employees: 95
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 32,791,817
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NKTX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NKTX
Upcoming Events for NKTX
Frequently Asked Questions for Nkarta Inc
What is the Nkarta Inc share price?

As of 16/04/21, shares in Nkarta Inc are trading at $34.87, giving the company a market capitalisation of £826.8m. This share price information is delayed by 15 minutes.

How has the Nkarta Inc share price performed this year?

Shares in Nkarta Inc are currently trading at $34.87 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Nkarta Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Nkarta Inc?

There are no analysts currently covering Nkarta Inc.

When will Nkarta Inc next release its financial results?

Nkarta Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Nkarta Inc dividend yield?

Nkarta Inc does not currently pay a dividend.

Does Nkarta Inc pay a dividend?

Nkarta Inc does not currently pay a dividend.

When does Nkarta Inc next pay dividends?

Nkarta Inc does not currently pay a dividend.

How do I buy Nkarta Inc shares?

To buy shares in Nkarta Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Nkarta Inc?

Shares in Nkarta Inc are currently trading at $34.87, giving the company a market capitalisation of £826.8m.

Where are Nkarta Inc shares listed? Where are Nkarta Inc shares listed?

Here are the trading details for Nkarta Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: NKTX
What kind of share is Nkarta Inc?

Based on an overall assessment of its quality, value and momentum, Nkarta Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Nkarta Inc share price forecast 2021?

Shares in Nkarta Inc are currently priced at $34.87. At that level they are trading at 0.125% discount to the analyst consensus target price of 0.00.

Analysts covering Nkarta Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.308 for the next financial year.

How can I tell whether the Nkarta Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nkarta Inc. Over the past six months, the relative strength of its shares against the market has been -10.46%. At the current price of $34.87, shares in Nkarta Inc are trading at -11.6% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Nkarta Inc PE Ratio?

We were not able to find PE ratio data for Nkarta Inc.

Who are the key directors of Nkarta Inc?

Nkarta Inc's management team is headed by:

Matthew Plunkett - SVP
Paul Hastings - PRE
Ralph Brandenberger - VPR
Nadir Mahmood - CFO
James Trager - CSO
Kanya Rajangam - OTH
Ali Behbahani - CHM
Tiba Aynechi - IND
Fouad Azzam - IND
Michael Dybbs - IND
Simeon George - IND
Leone Patterson - IND
Who are the major shareholders of Nkarta Inc?

Here are the top five shareholders of Nkarta Inc based on the size of their shareholding:

RA Capital Management, LP Hedge Fund
Percentage owned: 17.09% (5.61m shares)
GlaxoSmithKline PLC Corporation
Percentage owned: 9.61% (3.15m shares)
New Enterprise Associates (NEA) Venture Capital
Percentage owned: 8.86% (2.90m shares)
Novo Holdings A/S Venture Capital
Percentage owned: 8.52% (2.79m shares)
Life Sciences Partners Venture Capital
Percentage owned: 6.62% (2.17m shares)
Similar to NKTX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.